Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Thiocolchicoside + ibuprofen** is a fixed-dose combination drug containing the muscle relaxant thiocolchicoside and the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen. Thiocolchicoside is a synthetic sulfur-containing derivative of a natural colchicoside, acting as a centrally acting muscle relaxant. Ibuprofen is a widely used NSAID that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation. The combination is primarily indicated as an adjunctive treatment for **acute musculoskeletal conditions**, such as painful contractures and acute low back pain, where both muscle spasm and pain are present. Clinical studies show significant efficacy in improving pain, functional disability, and muscle contracture compared to monotherapy with either agent. The combination may be formulated as tablets, capsules, or granules for **oral administration**[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiocolchicoside + ibuprofen.